Homoeopathic drug pictures are developed by recording the symptomatic effects of homoeopathic remedies given to healthy volunteers (a 'proving'). In a double-blind randomized controlled trial we tested the hypothesis that individuals using an infinitesimal dilution of Belladonna (thirtieth potency, C30) would record more true symptoms, on a questionnaire that contained both true and false Belladonna proving symptoms, than those receiving placebo.
INTRODUCTION
A substance in homoeopathic dilution is said to produce characteristic symptoms in healthy individuals (a 'proving'), and can be used therapeutically in small or ultramolecular doses (below the Avogadro number) to abolish those same symptoms in people who are ill. The detailed record of proving symptoms forms the basis of the homoeopathic materia medicas, such as Kent and Boericket'2. Homoeopathic potencies are made by a process of serial dilution with succussion (a form of vigorous shaking) between dilutions. The most commonly used potency is 30C, which means the solute undergoes 30 serial dilutions of 1/100.
Hahnemann was the first to conduct systematic provings3. Experimental provings have varied considerably in their methodology and scientific design from large, highly organized, non-randomized, descriptive trials to informal or partial provings. As a consequence there has been much comment on the poor quality of proving studiesk8. The first proposal for a double-blind, placebo-controlled trial to re-prove Belladonna was published in 19069, and Walach in 1993 reported a double-blind, randomized, controlled cross-over clinical trial evaluating the effects of Belladonna C12 and Belladonna C30 versus placebo10-12, using a questionnaire with true and false symptoms. We were unaware of Walach's work when we began our study but will discuss its implications. Not all subjects 'prove'; the descriptive literature indicates that some 10-20% of individuals will prove accuratelyI3 14. Our hypothesis was that Belladonna C30 would cause more proving symptoms than placebo in healthy volunteers as assessed by a set of structured questions. Three researchers were involved: KG and GL were responsible for protocol development and the conduct of the trial; JLL was responsible for data analysis. METHOD Volunteers were recruited by personal contact and advertisements. The inclusion criteria were age 18-40 and stable good health. The exclusion criteria were selfreport of any illness, current use of any medical, homoeopathic or herbal remedy and use of any homoeopathic remedy in the past 4 weeks. Volunteers were told the purpose of the study but were not told which homoeopathic preparation would be used. Those who agreed to take part were immediately entered, randomized and began to take Belladonna C30 or placebo twice a day for two weeks while completing daily questionnaires ( Figure 1 ). Randomization was dictated by a computer program in blocks of 5 stratified by sex. An independent homoeopathic dispensary made up numbered identical bottles of identical homoeopathic pills. The bottles were then given to KG who gave them to the trial participants in order. The homoeopathic remedy was manufactured by Ainsworths Homoeopathic Pharmacy in accordance with Blackie Foundation guidelines. The unmedicated pills were manufactured with the solute for Belladonna C30. 
Questionnaire
The major proving symptoms for Belladonna were the basis for the questionnairel2. The questionnaire was piloted for one week on 5 individuals without any intervention; this was to determine the amount of 'background noise'. The initial pilot questionnaire included fifteen symptoms, ten of which were true or expected from Belladonna and five of which were false. Symptoms that were highly prevalent during the pilot study were removed from the final questionnaire (see Figure 1 ).
True symptoms were: flushed/hot; eyes hot/dry; agitated, restless; photophobia; toothache; dry mouth; tingling/shooting pains; dizziness; headache; nausea; suppressed appetite; stomach ache; diarrhoea. False symptoms were: less thirsty than usual; sweetish/metallic taste; great desire to eat fruit; sneezing; constipation; itchiness.
Outcome and analysis The primary outcome measure chosen was the difference in the number of true and false symptoms experienced by those taking Belladonna C30 compared with those taking placebo. A symptom counted if the appropriate box was ticked during any of the 14 days. Secondary outcome measures were: * Proportion of individuals experiencing a proving reaction in each group. This was defined as at least two symptoms on at least 2 consecutive days with no more than one false symptom during the 14 days of the study period. * Difference in the number of false symptoms experienced by both groups, and number of spontaneously recorded symptoms (classified as true or false with reference to Boericke and Kent). We recorded information about intercurrent illness, smoking, tea and coffee consumption and alcohol consumption. Missing observations were assumed to mean that no symptoms were recorded. The experimental groups were compared by use of Fisher's exact two-tailed test.
RESULTS
60 volunteers were randomized and 47 provided follow-up data. We were unable to determine why 13 volunteers were lost to follow-up. Baseline data are given in Table 1 . For unknown reasons there was a much higher drop-out rate in the Belladonna group (33%) than in those receiving placebo (10%). The groups were well matched for age (all participants were between 21 and 23), smoking and caffeine intake. We were not aware that any of the participants had previously used Belladonna C30.
Symptoms recorded
Volunteers experienced symptoms on a total of 260 symptom days, 175 of them true symptoms and 85 false symptoms. 14 individuals (5 Belladonna C30, 9 placebo) reported no symptoms. 43 reported at least one symptom ( Table 2) .
Spontaneously recorded symptoms were noted on 14 days (0.7%) in both Belladonna and placebo groups with no false symptoms in the Belladonna group and 3 (0.8%) in the placebo group. There is no significant difference between the two groups in the symptoms reported (confidence intervals cannot be calculated because the distributions are non-normal). Visual inspection of the data gives some clues as to the symptoms which might be most sensitive to Belladonna: hot or dry eyes, photophobia, evening toothache and tingling/shooting pains in the limbs seem to occur more frequently on Belladonna than placebo. None of the false symptoms occurred significantly more frequently in those receiving Belladonna than in those who received placebo.
Proving reactions
According to our definition of proving, 4 volunteers proved in the Belladonna C30 group and 1 in the placebo group (Fisher's exact test two-tailed P=0. 14; mid P=0.11). One individual who did not complete a full set of data withdrew after 7 days because of a severe proving reaction involving two true symptoms and no false symptoms; if this individual is included in the data analysis, 5 people in the group receiving Belladonna C30 proved, generating a statistically significant result (P=0.07; mid P=0.04).
Smoking, caffeine and alcohol intake were evenly distributed between the Belladonna and placebo groups and did not affect outcome.
DISCUSSION
Homoeopathic proving underpins the clinical practice of homoeopathy but its dynamics and methodology are complexls. Only a small percentage of individuals actively prove; Walach estimates that 1% of individuals proved in his study'2 while we have suggested that between 10 and 20% are likely to actively prove. It is therefore unsurprising that the overall frequency of true and false symptoms comprises a blunt instrument through which to evaluate outcome. However, our pilot study suggests that we may be able to differentiate Belladonna C30 from placebo by looking at individual proving reactions. If, for instance, we assume a proving rate of 20%, we will need 65 individuals in each group to obtain 5% significance at 80% power. The study of Walach et a]. 12 involved a similar methodology but was a cross-over study involving two homoeopathic potencies. He entered 17 people-too few to allow development of a proper model. The effect of cross-over may have served to confuse, since homoeopathic remedies may be effective for an unpredictable period. We gave our remedies to young, healthy and largely non-smoking volunteers in whom we would expect a high rate of proving, while Walach used a wider age range who might be less likely to prove. However Walach was the first to develop the idea of closed questionnaires including both true and false symptoms.
Our pilot study could now be used as the basis for a larger and more definitive study. We believe that we should use an equal number of true and false symptoms, and that the questionnaire should be piloted more rigorously for 'background noise'. We have attempted to use other definitions of proving reactions to look at the data post hoc, but have found that they were less specific. We therefore believe that our definition of a proving reaction in the context of this study is valuable, although it may need future modification if volunteers fail to complete the study because of a proving reaction.
